IMAB I-Mab Biopharma: רווח למניה ב-12 החודשים האחרונים

The price action of I-Mab (IMAB) securities reflects the EPS TTM dynamics, which currently stand at 0.00. I-Mab leverages patent protection and low demand sensitivity to therapy costs, utilizing a combination of Chinese R&D centers and a US clinic. Business development depends on the effectiveness of the immunological portfolio, government support, and external financing. Expected results from new tests will provide a key catalyst following the completion of asset reorganization.

I-Mab has transitioned to the autonomous development of its US oncology programs following the spin-off from its Chinese division. This transformation is reflected in the trend of the rolling annual growth rate of net income per share. This metric measures the percentage change in TTM earnings, allowing the separation of speculative noise from real growth in business efficiency. An analysis of the 12-month YoY net income per share change reveals whether the model is resilient or subject to one-time anomalies.